Funding profile · Hearing devices

Auricle

Six years old, two people, no Regulation D filing of its own. The one Form D that data vendors attach to this company was filed by a different company with the same name.

$275,371NIH SBIR Phase I award, the only audited dollar figure in the record
$0Regulation D capital on file with the SEC for Auricle Health Inc.
$500KRaised to date, as reported by PitchBook
$975KTotal funding raised, as reported by Caplight

Data as of September 22, 2026. Company-reported and vendor-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Summer 2020 Stanford Biodesign Summer Extension, hosted at Fogarty Innovation Not disclosed Stanford Biodesign; Fogarty Innovation Incubator report
Winter 2021 Y Combinator batch W21 Not disclosed Y Combinator YC directory
Undated Early stage VC Not disclosed Not named PitchBook
Apr 5, 2023 Accelerator Not disclosed Not named PitchBook, Caplight
Aug 2024 NIH SBIR Phase I, non-dilutive $275,371 NIDCD NIH RePORTER
Standing Named backers on the company website Not disclosed Y Combinator, StartX, Fogarty Innovation; DigiLife lists Auricle in its portfolio Company, investor
Any date Form D offering by Auricle Health Inc. None None No filing

What the filings show

EDGAR holds no filing of any type for Auricle Health Inc. A company search and a full text search on September 22, 2026 both returned nothing. The single Form D that carries the name Auricle belongs to another issuer and is set out here so it is not counted twice.

Auricle, Inc. · Form D · filed Nov 22, 2021

Match
Different company. Tinnitus device developer, not the hearing implant company profiled here.
First sale
May 18, 2021
Offered
$350,000 debt
Sold
$350,000 · $0 remaining
Investors
3 · average about $116,667
Exemption
Rule 506(b)
Related persons
Jonathan T. Pearson (executive officer, director), signing as Chief Executive Officer
Issuer detail
Delaware corporation, incorporated 2019, address 209 Dellbrook Ave., San Francisco; industry given as Other Technology
Filing
SEC EDGAR, CIK 0001894053

Reading the filings

  1. The Form D is not this company.Auricle Health Inc. was founded in 2020 by Francis Wong and Jay Dhuldhoya and its NIH award lists Oakland, California. The Form D issuer is a Delaware corporation incorporated in 2019, run from a residential address in San Francisco, with Jonathan T. Pearson signing as chief executive. Pearson is chief executive of the tinnitus company that also holds NIH award 1R43DC022809-01. Two companies, two sets of records, one label.
  2. The two published totals disagree, and one is contaminated.PitchBook reports $500,000 raised to date. Caplight reports $975,000, a gap of $475,000. Caplight also lists a Seed round dated November 22, 2021, which is the exact filing date of the other company’s Form D. That is the likeliest source of the extra money.
  3. Federal money is the only figure with a paper trail.$275,371 from NIDCD in August 2024 under R43DC021615, an SBIR Phase I. The period of performance was extended from July 31, 2025 to July 31, 2026, which points to work running behind the original plan rather than to new money.
  4. One vendor has the company dead.PitchBook marks Auricle Out of Business with a date of November 1, 2024. The federal grant ran past that date, the company opened a clinical study on June 2, 2025, the trial record was verified as recruiting in February 2026, the YC directory listed the company as Active with two people on September 22, 2026, and the website resolves. The Out of Business flag is not supported by the record.
  5. Absence of a Form D is not absence of money.Companies that raise under Section 4(a)(2), or on an accelerator’s standard instrument, may file nothing. Y Combinator, StartX and Fogarty Innovation are named as backers on the company’s own site, and DigiLife lists Auricle in its portfolio, yet none of that appears in EDGAR.
  6. Grant money is a large share of the documented total.Against PitchBook’s $500,000 of private capital, the single NIH award is $275,371, roughly 35% of the combined $775,371. For a device company with no product and no revenue, that ratio says the balance sheet is small.

Commercial signals

Signal Detail Source type
Product None on the market. The implant is in development; Phase I work covers electrode design and animal testing. Public record
Revenue None reported. No customer named. Listings that file Auricle under revenue cycle software do not match any primary record. Not found
Regulatory No FDA 510(k) and no PMA record. Not found
Clinical NCT07402941, 18 adults, Cleveland Clinic, started Jun 2, 2025, recruiting as verified Feb 2026. Public record
Headcount 2 per the YC directory, 2 to 10 per LinkedIn, 10 per PitchBook. Sources disagree
Address San Francisco per YC, Oakland per the NIH award and PitchBook, Mountain View per LinkedIn. Sources disagree

What to watch

  • A first Form D under Auricle Health Inc. It would be due within 15 days of a first sale.
  • An SBIR Phase II award. Phase I ended July 31, 2026.
  • Results or an update on NCT07402941, whose primary completion was estimated for May 2026.
  • Whether PitchBook clears the Out of Business flag, and whether Caplight separates the two companies.

The Auricle story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • AudioFocus: Also in Medical Devices. A Y Combinator company built to lift the voices at your table out of the roar of a crowded room
  • Zenflow: Also in Medical Devices. A small nitinol coil that props open the prostatic urethra, delivered through a flexible scope and removable at any time
  • Corveus Medical: Also in Medical Devices. A Houston company building a catheter that deactivates one sympathetic nerve to relieve congestion in heart failure
  • Andromeda Surgical: Also in Medical Devices. A tablet-driven robot that guides urologists through one of the hardest operations in their specialty

Sources

  1. Public recordForm D, Auricle, Inc., CIK 0001894053, accession 0001894053-21-000001SEC · Nov 22, 2021
  2. Public recordEDGAR company search and full text search for Auricle and Auricle HealthSEC · Sep 22, 2026
  3. Public recordNIH RePORTER 1R43DC021615-01, awarded to Auricle Health Inc.NIDCD · FY2024
  4. Public recordNIH RePORTER 1R43DC022809-01, awarded to Auricle, Inc.NIDCD · FY2025
  5. Public recordGrant record R43DC021615, amendment note on the extended end dateHigherGov · accessed Sep 22, 2026
  6. Public recordClinicalTrials.gov NCT07402941First posted Feb 11, 2026
  7. IndependentAuricle company profile with deal history and Out of Business flagPitchBook · accessed Sep 22, 2026
  8. IndependentAuricle funding rounds and investor listCaplight · accessed Sep 22, 2026
  9. IndependentFogarty Institute Helps Advance Promising Projects from Stanford BiodesignFogarty Innovation · Aug 20, 2020
  10. CompanyAuricle website home page naming Y Combinator, StartX and Fogarty Innovationauricle.com · accessed Sep 22, 2026
  11. CompanyAuricle company and jobs pages showing batch W21, status Active, team size 2Y Combinator · Sep 22, 2026
  12. InvestorPortfolio page listing AuricleDigiLife · accessed Sep 22, 2026

Compiled from SEC, NIH and ClinicalTrials.gov public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Auricle. This page is not an offer to sell or a recommendation to buy any security.